Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
A Multicentre Primary & Booster Vaccination Study of GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB® & MenC Conjugate Licensed Vaccine When Given According to the 2-4-6 Month Schedule to Healthy Infants With Booster Dose at 12 to 15 Months
Sponsor: GlaxoSmithKline
A PHASE2 clinical study on Haemophilus Influenzae Type b and Neisseria Meningitidis, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2005. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Carlton, Australia
- • North Adelaide, Australia
- • Perth, Australia